Helius Medical Tech Stock (NASDAQ:HSDT), Trade Ideas

Helius Medical Tech

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

HSDT

Government

News

Health Care

Movers

General

Helius Medical partners with Lovell Govt Services to provide PoNS device to federal healthcare systems. PoNS, a short-term treatment for gait deficit in MS, shows promising real-world results. Seeking FDA authorization for stroke treatment. HSDT shares surge 38% in premarket trading.

Why Is Nano-Cap Helius Medical Stock Trading Higher On Wednesday?

Penny Stocks

Small Cap

Intraday Update

Markets

Trading Ideas

AADI

AIMD

AKRO

APVO

ASTR

BBAI

BCDA

BIVI

BTDR

BYND

CMCL

COIN

CRDF

CRML

DWAC

ETNB

FUFU

IFBD

JAGX

JOAN

LIFW

MGEE

MINM

MSTR

NKTR

NYCB

OCEA

PHUN

PLTK

QNRX

RELI

RENB

RNLX

RVNC

SABR

SAVE

SBFM

SMCI

TRNR

VANI

ZJYL

Shares of  Bitdeer Technologies Group  (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.

Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

bz_pharma_briefs

Helius Medical Technologies is a neurotech company in the medical device field focused on neurologic deficits.

Why Is Neurotech-Focused Helius Medical Trading Higher On Monday?

Helius Medical Technologies, Inc. - Class A Common Stock

Helius Medical Technologies Inc

Helius Medical Technologies Inc Warrants (02/02/2026)

Keybanc analyst Sophie Karp downgrades Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) from Overweight to Sector Weight.

Downgrades

Analyst Ratings

NOVA

Keybanc Downgrades Sunnova Energy Intl to Sector Weight

WIIM

Shares of life sciences tools stocks are trading higher following strong earnings from Danaher.

Loop Capital analyst Yun Kim downgrades Matterport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTTR#NASDAQ">MTTR</a>) from Buy to Hold and raises the price target from $5 to $5.5.

Price Target

MTTR

Loop Capital Downgrades Matterport to Hold, Raises Price Target to $5.5

RNAC

Cartesian Therapeutics shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $39 price target.

https://www.reuters.com/business/autos-transportation/tesla-aims-cut-400-jobs-germany-via-voluntary-programme-2024-04-23/#:~:text=FRANKFURT%2C%20April%2023%20(Reuters),programme%20instead%20of%20forced%20layoffs.

TSLA

'Tesla aims to cut 400 jobs in Germany via voluntary program' -Reuters

Halliburton Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) reported&nbsp;first-quarter 2024 revenue growth&nbsp;of 2.2% year-over-year to $5.804 billion,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38374599/halliburton-announces-first-quarter-2024-results" rel="noreferrer noopener">beating the consensus of $5.668 billion.</a>
Completion and Production revenue was $3.4 billion, slightly down from 2023. Operating income rose 3% to $688 million, fueled by diverse global service improvements and higher product sales.
Drilling and Evaluation revenue rose 7% to $2.4 billion, with operating income up 8% at $398 million, driven by increased drilling services in the Middle East and North America despite some regional drops.
HAL&#8217;s North&nbsp;America&nbsp;revenue fell 8% to $2.5 billion due to decreased U.S. pressure pumping and regional wireline activity.
International revenue was $3.3 billion, an increase of 12% YoY, with revenue from Latin America +21%, Europe/Africa +10% and Middle East/Asia +6%.
Total operating income rose 1% to $987 million, and margin contracted by 20 bps to 17%.
The company repurchased ~$250 million of its common stock during the quarter.
Adjusted EPS was $0.76,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of $0.74.</a>
Operating cash flow stood at $487 million for the quarter compared to $122 million a year ago, and free cash flow was $206 million.
&#8220;Activity in North America recovered from fourth-quarter lows, and our international business delivered its 11th consecutive quarter of year-on-year growth. Our customers&#8217; multi-year activity plans across markets and asset types confirms my confidence in the strength and duration of this upcycle,&#8221; commented Jeff Miller, Chairman, President, and CEO.
In its conference call, Halliburton said it expects 2024 revenue growth in the low double digits.
Price Action: HAL shares are trading lower by 0.10% at $38.68 at the last check Tuesday.
Photo via Wikimedia Commons

Earnings

Guidance

Halliburton's Strong International Performance Lifts Q1 Revenue Amid North American Challenges

VLRS

Controladora Vuela shares are trading higher after the company reported better-than-expected Q1 financial results.

Monday, the FDA approved&nbsp;ImmunityBio Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) Anktiva (N-803, or&nbsp;nogapendekin&nbsp;alfa&nbsp;inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS),&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38368486/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresp" rel="noreferrer noopener">with or without papillary tumors</a>.
The drug is combined with the BCG vaccine, mainly used against tuberculosis and as a&nbsp;common&nbsp;treatment for some forms of bladder cancer.
Last year in May, the FDA issued a complete response letter to&nbsp;Anktiva plus BCG treatment, citing deficiencies related to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/05/32341596/stock-loses-50-in-one-trading-session-why-are-immunitybio-shares-tanking-today" rel="noreferrer noopener">contract manufacturing organizations</a>.
&#8220;The FDA&#8217;s approval of ANKTIVA marks our launch of a next-generation immunotherapy beyond checkpoint inhibitors,&#8221; said Patrick Soon-Shiong, Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio.&nbsp;
The company says Anktiva is a first-in-class IL-15 agonist immunotherapy for NMIBC and received FDA Breakthrough Therapy Designation and approval based on the safety and efficacy outcome of complete responses (CR) and duration of complete response (DOR).&nbsp;
The CR rate for the 77 evaluable patients was 62%, with the upper end of the confidence interval being 73%.&nbsp;
The duration of the complete response as of the November 2023 cut-off was more than 47 months and is ongoing to date.&nbsp;
The company adds that the prolonged duration of complete response results beyond 24 months with ANKTIVA and BCG&nbsp;exceeds the benchmark&nbsp;for the magnitude of meaningful clinical results suggested by a panel of experts at the IBCG.
The duration of response is ongoing, so the final median duration of response has yet to be determined. 58% of patients with CR had a DOR ≥ 12 months, and 40% had a DOR ≥ 24 months.
Anktiva is expected to be available in the U.S. by mid-May 2024.
Price Action:&nbsp;IBRX shares are up 4.65% at $5.17 at the last check Tuesday.

Biotech

IBRX

FDA Approves ImmunityBio's Bladder Cancer Drug, Stock Rallies

Jack Fox, the Pro Bowl punter for the Detroit Lions and upcoming speaker at <a href="https://www.benzinga.com/nfldraft/" target="_blank" rel="noreferrer noopener">Benzinga&#8217;s 2024 Detriot Draft</a> event, epitomizes the perseverance and excellence of professional sports. 
Transitioning from an undrafted player in 2019 to becoming the league&#8217;s highest-paid punter, Fox&#8217;s journey underscores his commitment and prowess on the field. 
Initially signing briefly with the Kansas City Chiefs, Fox found his stride with the Lions, where he was quickly recognized for his powerful punting, securing a Pro Bowl selection shortly after his debut season.
<h3 class="wp-block-heading">Strategic Contract Renewal</h3>
In 2022, Fox reinforced his value to the Lions through a three-year contract extension valued at $11.325 million, highlighting his integral role on the team. His exceptional ability to maintain an average of 49.1 yards per punt has been critical in setting team records and establishing him as a dependable player during strategic plays, including booming fake punts​.
<h3 class="wp-block-heading">Commitment to Craft and Community</h3>
Fox&#8217;s dedication extends beyond the playing field. He trains intensively in Alabama each offseason to enhance his athletic performance for forthcoming seasons. His community involvement is also notable; he organizes and leads camps for aspiring young punters and kickers in the Detroit area, demonstrating his commitment to developing the next generation of athletes.
<h3 class="wp-block-heading">Why You Should Attend Benzinga&#8217;s Draft Event</h3>
Benzinga is a leader in the events space. It has the experience to connect its audience with speakers, panelists, and other attendees. The financial media company has organized 32 &#8216;Business Titans&#8217; events and is known globally for its popular, high-profile gatherings.
The Benzinga Sports Business Titans event features a strong lineup of speakers from the sports and business worlds. Each guest will share their journeys of entrepreneurship and investments.
Athletes, social media stars, and business leaders will share advice and provide a behind-the-scenes look at how sports and business often intersect. This event features former and current athletes and critical business voices. Join Benzinga for the 2024 Sports Business Titans.&nbsp;<a href="https://www.benzinga.com/nfldraft/" target="_blank" rel="noreferrer noopener">Get tickets here</a>.
Image: Football.Shutterstock

Sports

Events

Star Detroit Lions Punter To Speak At Benzinga's Detroit Draft Event

Loop Capital analyst Yun Kim initiates coverage on MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Buy rating and announces Price Target of $415.

Initiation

Loop Capital Initiates Coverage On MongoDB with Buy Rating, Announces Price Target of $415

Benchmark analyst Reuben Garner reiterates Quanex Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) with a Buy and maintains $38 price target.

Reiteration

Benchmark Reiterates Buy on Quanex Building Prods, Maintains $38 Price Target

By <a href="https://roboforex.com/?utm_source=benzinga.com&amp;utm_medium=pr&amp;utm_campaign=rf_en_external_article_23042024&amp;utm_content=analysis&amp;utm_term=forecast">RoboForex</a> Analytical Department
The AUD/USD pair is experiencing upward momentum for the second consecutive day, reaching a one-week high near 0.6453 on Tuesday. This positive movement comes after a period of rapid decline and is supported by encouraging economic data from Australia.
The latest manufacturing PMI report for April significantly contributed to the Australian dollar&#39;s appreciation. It showed an increase to 49.9 points, up from 47.3 the previous month. This improvement brings the manufacturing sector close to the critical 50.0 threshold, distinguishing between the industry&#39;s growth and contraction. Additionally, the services PMI reported the most robust expansion in the last three months, and the private sector experienced its fastest growth in two years during April.
These robust economic reports not only indicate a resilient economy but also carry pro-inflationary implications. They bolster the outlook that the Reserve Bank of Australia (RBA) may maintain higher interest rates for an extended period to manage inflationary pressures effectively.
Investors will also pay attention to the upcoming release of inflation statistics later in the week, which will provide further insights into the economic factors influencing the RBA&#39;s monetary policy decisions.
Moreover, the Australian dollar&#39;s gains were further supported by a reduction in investor concerns over geopolitical risks in the Middle East, contributing to a more favourable risk environment.
<h3>Technical Analysis Of AUD/USD</h3>
<a href="https://www.benzinga.com/files/u117641/audusdh4_5.png"><img alt="" src="https://www.benzinga.com/files/u117641/audusdh4_5.png" style="height:280px; width:624px" /></a>
On the H4 chart, the AUD/USD pair completed a declining wave to 0.6362. A corrective movement towards 0.6471 is underway. Upon completion of this correction, a continuation of the downward trend towards 0.6300 is anticipated. The MACD indicator supports this bearish outlook despite its signal line being above zero, which typically suggests growth potential.
<a href="https://www.benzinga.com/files/u117641/audusdh1_4.png"><img alt="" src="https://www.benzinga.com/files/u117641/audusdh1_4.png" style="height:280px; width:624px" /></a>
On the H1 chart, a consolidation range has been formed around 0.6417. A breakout above this range could lead to a rise towards 0.6471. Following this peak, a new downward wave to 0.6363 is expected. Breaking below this level may pave the way to reach 0.6300. The Stochastic oscillator, with its signal line currently below 80 and pointing downwards, confirms this potential downward trajectory.
Disclaimer
Any forecasts contained herein are based on the author&#39;s particular opinion. This analysis may not be treated as trading advice. RoboForex bears no responsibility for trading results based on trading recommendations and reviews contained herein.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Technicals

Forex

Australian Dollar Rises On Strong Economic Indicators

KULR

KULR Technology Group shares are trading higher after the company announced it delivered on an immediate basis, a power cell battery deployment order for AI-enabled drone and advanced air mobility missions in Ukraine.

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 0.5% on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.23% to 38,328.19 while the NASDAQ rose 0.51% to 15,529.65. The S&amp;P 500 also rose, gaining, 0.45% to 5,033.06.
Check This Out: <a href="https://www.benzinga.com/news/24/04/38376714/wall-streets-most-accurate-analysts-views-on-3-energy-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Energy Stocks With Over 3% Dividend Yields</a>
Leading and Lagging Sectors Communication services shares climbed by 1% on Tuesday.
In trading on Tuesday, materials shares fell by 0.9%.
Top Headline PepsiCo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) reported upbeat earnings for its first quarter.
PepsiCo reported first-quarter FY24 sales growth of 2.3% year-on-year to $18.25 billion, beating the analyst consensus estimate of $18.079 billion. Adjusted EPS of $1.61 beat the consensus estimate of $1.52.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares shot up 98% to $0.2410 after the company announced that it has been chosen to supply its DriveMod Tuggers for industrial automation to John Deere&#8217;s operation in Dubuque, Iowa.</li>
<li>Shares of Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) got a boost, surging 51% to $0.0690 after falling 10% on Monday</li>
<li>Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares were also up, gaining 43% to $7.03 after the company&#8217;s entered a collaboration with Strand Life Sciences.</li>
</ul>
<h3 class="wp-block-heading">Equities Trading DOWN</h3>
<ul>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares dropped 48% to $0.0658. Greenwave Technology Solutions disclosed that it further strengthened its balance sheet by approximately $12 million.</li>
<li>Shares of Abeona Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) were down 44% to $4.1376 after the company announced the FDA issued a Complete Response Letter in response to the company&#8217;s Biologics License Application for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa.</li>
<li>Lichen China Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) was down, falling 46% to $0.5251.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38377428/over-10m-bet-on-this-healthcare-stock-check-out-these-4-stocks-insiders-are-buying">Over $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying</a>
Commodities In commodity news, oil traded down 0.3% to $81.69 while gold traded down 1.2% at $2,318.50.
Silver traded down 1% to $26.965 on Tuesday, while copper fell 1.1% to $4.4250.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.9%, London's FTSE 100 rose 0.6% while Spain's IBEX 35 Index climbed 1.4% The German DAX gained 1.1% French CAC 40 rose 0.6% while Italy's FTSE MIB Index jumped 1.4%.
Eurozone's government deficit to GDP ratio fell to 3.6% in 2023 compared to a revised 3.7% in the prior year.
Asia Pacific Markets
Asian markets closed mostly higher on Tuesday, with Japan's Nikkei 225 gaining 0.30%, Hong Kong's Hang Seng Index gaining 1.92%, China's Shanghai Composite falling 0.74% and India's S&amp;P BSE Sensex gaining 0.12%.
The People&#8217;s Bank of China maintained its key lending rates at the April fixing.
Economics
Data on new home sales will be released at 10:00 a.m. ET.
Now Read This: <a href="https://www.benzinga.com/news/24/04/38376630/amazon-com-united-airlines-and-2-other-stocks-insiders-are-selling">Amazon.com, United Airlines And 2 Other Stocks Insiders Are Selling</a>

Eurozone

Commodities

ABEO

GWAV

LICN

PALI

PEGY

US Stocks Higher; PepsiCo Posts Upbeat Earnings

Barclays analyst Andrew Mok downgrades Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) from Equal-Weight to Underweight and announces $83 price target.

ADUS

Barclays Downgrades Addus HomeCare to Underweight, Announces $83 Price Target

Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) will be reporting its first-quarter earnings on April 24 <a href="https://www.benzinga.com/calendars/earnings?tickers=F">after market hours</a>.
Wall Street expects 50 cents in EPS and $40.7 billion in revenues.
Ford shares haven&#8217;t gained much over the past year — up just 7.46%. So far this year, the stock is up just 7.2%. 
Here's how the stock is technical setup ahead of Q1 earnings, and how it currently maps against Wall Street estimates.
Read More: <a href="https://www.benzinga.com/news/earnings/24/04/38377405/ford-stock-is-trading-higher-tuesday-whats-going-on">Ford Stock Is Trading Higher Tuesday: What&#8217;s Going On?</a>
<h3 class="wp-block-heading">Ford Stock Technical Setup Ahead Of Q1 Earnings</h3>
The technical analysis of Ford stock points towards a bullish trend. The share price is currently trading above its 8, 20, and 50-day exponential moving averages, indicating strong bullish momentum and significant buying pressure.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="626" height="456" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/23085100/Screenshot-2024-04-23-at-6.04.14-PM.jpg" alt="" class="wp-image-304318" style="width:800px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/23085100/Screenshot-2024-04-23-at-6.04.14-PM.jpg 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/23085100/Screenshot-2024-04-23-at-6.04.14-PM-300x219.jpg 300w" sizes="(max-width: 626px) 100vw, 626px" /></figure>
<a target="_blank" href="https://pro.benzinga.com/dashboard" rel="noreferrer noopener">Chart: Benzinga Pro</a>
Additionally, the stock&#8217;s price of 12.88 is above its eight-day simple moving average of $12.39, its 20-day SMA of $12.88, and its 50-day SMA of 12.59, all signaling bullish sentiments.
Furthermore, the stock&#8217;s price exceeds its 200-day simple moving average of $12.09, reinforcing the bullish sentiment. 
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="626" height="456" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/23085119/Screenshot-2024-04-23-at-6.05.53-PM.jpg" alt="" class="wp-image-304319" style="width:800px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/23085119/Screenshot-2024-04-23-at-6.05.53-PM.jpg 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/23085119/Screenshot-2024-04-23-at-6.05.53-PM-300x219.jpg 300w" sizes="(max-width: 626px) 100vw, 626px" /></figure>
<a target="_blank" href="https://pro.benzinga.com/dashboard" rel="noreferrer noopener">Chart: Benzinga Pro</a>
However, it&#8217;s worth noting that the Moving Average Convergence Divergence (MACD) indicator is -0.03, suggesting a bearish signal. Moreover, the Relative Strength Index (RSI) is at 57.26, treading towards the above 70 zone where Ford Motor stock would be overbought. 
Despite these cautionary signals, the Bollinger Bands suggest bullish momentum with Ford price crossing over from the lower band (bearish) to the upper band (bullish) recently. 
Overall, while there are some conflicting signals, the majority of technical indicators support a bullish outlook for Ford stock.
<h3 class="wp-block-heading">Ford Analysts Consensus Ratings</h3>
Ratings &amp; Consensus Estimates: <a href="https://www.benzinga.com/quote/F/analyst-ratings">The consensus analyst rating</a> on Ford stock stands at a Buy currently with a price target of $13.75.
However, per the last three analyst ratings on the stock that were released Feb. 13 onwards from Barclays, Piper Sandler, and Morgan Stanley, the average price target stands at $15. This implies a 14.24% upside for Ford stock.
F Price Action: Ford stock closed trading of April 22 at $12.88, up 6.1%. 
The company&#8217;s stock popped higher during pre-market hours Tuesday, driven by optimism from General Motors Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) earnings. Shares of the Ford rival were trading higher pre-market, up 4.5% by 8 AM ET, after it delivered a beat Q1 earnings estimates. 
The company delivered a 22.43% surprise on EPS and a 2.71% surprise on revenue. General Motors also raised its 2024 outlook. It raised its adjusted earnings guidance from a range of $8.50 to $9.50 per share to a new range of $9 to $10 per share.
Read Next: <a href="https://www.benzinga.com/news/earnings/24/04/38374783/wall-street-set-to-open-higher-as-tesla-to-kick-off-magnificent-7-earnings-why-this-analyst-thinks-">Wall Street Set To Open Higher As Tesla Kicks Off &#8216;Magnificent 7&#8217; Earnings: Why This Analyst Thinks Market Weakness Is A &#8216;Healthy Pullback&#8217;</a>
Image: Shutterstock

Analyst Color

Ford Enjoys Bullish Momentum But Faces Buying Pressure Ahead Of Q1 Earnings

Benchmark analyst Subash Chandra reiterates Magnolia Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>) with a Hold.

Benchmark Reiterates Hold on Magnolia Oil & Gas

Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) on Monday quietly sneaked in a price benefit to its users even as <a href="https://www.benzinga.com/markets/equities/24/04/38345362/tesla-slashes-model-s-x-and-y-prices-in-us-by-2-000-in-late-friday-move-as-volume-growth-turns-n">industry leader Tesla announced price cuts over the weekend.</a>
What Happened: Commemorating the &#8216;Earth Day,&#8217; observed every year on April 22, Rivian said it would start offering a discount of up to $5,000 on qualifying new R1 models when customers trade in select gas-powered vehicles. 
Additionally, buyers become eligible for a year of charging on the Rivian Adventure Network at no additional cost.
The discount, ranging from $1,000 to $5,000 is made available to customers in the U.S. and Canada and is applicable for deliveries taken between Monday (April 22) and June 30. The details of the trims and the applicable discounts are as follows:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td></td>
<td>Discount (USD)</td>
<td>Discount (CAD)</td>
</tr>
<tr>
<td>R1T Standard, Standard+ Pack</td>
<td>$3,000</td>
<td>C$4,500</td>
</tr>
<tr>
<td>R1T Large Pack</td>
<td>$4,000</td>
<td>C$6,000 </td>
</tr>
<tr>
<td>R1S Large Pack</td>
<td>$5,000</td>
<td>C$7,500</td>
</tr>
<tr>
<td>R1S Large Pack</td>
<td>$1,000</td>
<td>C$1,500</td>
</tr>
</tbody>
</table>
</figure>
For availing the vehicle must be selected and purchased or leased through Rivian's online Shop.
Vehicles eligible for trade-ins are:
<ul>
<li>2018 or newer Ford: F-150, Explorer, Expedition, Bronco (excluding Bronco Sport)</li>
<li>2018 or newer Toyota: Tacoma, Tundra, Highlander, 4Runner</li>
<li>2018 or newer Jeep: Grand Cherokee, Wrangler, Gladiator</li>
<li>2018 or newer Audi: Q5, Q7, Q8</li>
<li>2018 or newer BMW: X3, X5, X7</li>
</ul>
Rivian said the Earth Day is a &#8220;time to celebrate the planet we call home and think about ways to preserve it for generations&nbsp;to&nbsp;come. We want to help you get into a more environmentally friendly, zero-emissions Rivian&nbsp;vehicle.&#8221;
See Also: <a href="https://www.benzinga.com/money/best-electric-vehicle-stocks">Best Electric Vehicles</a>
Why It&#8217;s Important: Tesla announced over the weekend a flat $2,000 cut in the prices of all trims of its Model Y, S and X vehicles. It isn&#8217;t quite apparent whether Rivian&#8217;s own discount is a reactionary move. At least the company did not project it as a configurator price cut and structured it as a limited period discount. To top it, it is a trade-in benefit.
Fund Manager Gary Black is not a fan of configurator price cuts, and following Tesla&#8217;s weekend price cuts, he warned that rivals would match the move. Tesla, therefore, will unlikely see any volume benefit, he added.
Chinese EV startup Li Auto, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) on Monday <a href="https://www.benzinga.com/markets/asia/24/04/38351314/did-tesla-just-trigger-another-brutal-price-war-in-china-li-auto-blinks-first-with-up-to-4-000-disco">announced sharp price cuts for almost its entire lineup,</a> towing in line with Tesla&#8217;s cuts in the country.
In premarket trading on Tuesday, Tesla shares slipped 0.46% to $8.75, according to<a href="https://benzinga.grsm.io/lxquj26b2sag"> Benzinga Pro data.</a>
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="http://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next: <a href="https://www.benzinga.com/news/24/04/38353241/rivian-may-bring-back-a-beloved-feature-modified-tank-turn-for-off-roading">Rivian May Bring Back A Beloved Feature With A Twist: Modified Tank Turn For Off-Roading</a>
Photo by Tada Images on Shutterstock

Equities

Tech

RIVN

Rivian's Earth-Day Offer: Trade In Your Gas-Powered Car And Get Up To $5K Off On R1 EV

<h4>Key Takeaways:</h4>
<ul>
<li>Fosun Tourism said business volume at its Atlantis Sanya mega-resort and Club Med chain rose 4.5% and 15.2%, respectively, in the first quarter</li>
<li>The company&rsquo;s shares are trading near an all-time low, following reports earlier this year that its two major assets may be up for sale to raise cash for its debt-strapped parent</li>
</ul>
By Doug Young
There&rsquo;s not much fun these days at&nbsp;Fosun Tourism Group&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/fsngf#OTC">FSNGF</a>), one of China&rsquo;s leading tourism companies and owner of the Club Med resort chain.
The company&rsquo;s latest&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0422/2024042201483.pdf">quarterly update</a>&nbsp;shows it&rsquo;s suffering from a post-Covid hangover, with its China business significantly underperforming the market. Its global business, anchored by the Club Med chain, did slightly better, but was nothing to write home about either. Meantime, the company&rsquo;s stock is down more than 40% this year and now trades at all-time lows, in sharp contrast to Chinese peers that have mostly posted strong gains this year.
So, why all the gloom at a company whose formation dates back to the roughly $1 billion purchase of Club Med in 2015 by&nbsp;Fosun International&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/fosuf#OTC">FOSUF</a>), one of China&rsquo;s leading conglomerates? While the latest quarterly operating data isn&rsquo;t too exciting, it hardly explains Fosun Tourism&rsquo;s recent fall from grace in the investment community.
The biggest factor behind the gloom probably owes to reports in March that Fosun International was considering selling part of Club Med, as well as Fosun Tourism&rsquo;s other major asset, its Atlantis Sanya mega-resort, to raise cash to pay down its massive debt. Thus, anyone who holds Fosun Tourism stock now doesn&rsquo;t really know if the company will still own one or both of its major assets at this time next year.
At the same time, the people at Fosun Tourism are probably having difficulty staying focused on their business while knowing major changes could soon be coming.
All that said, we&rsquo;ll return to Fosun Tourism&rsquo;s first-quarter update that provides one of the first real indicators of how China&rsquo;s tourism industry will fare in the post-Covid era. This year&rsquo;s first quarter is significant in China, since it marks the first time that the latest data and year-ago comparisons are both in the country&rsquo;s post-Covid period.
That means that Covid-era volatility should be largely gone from most Chinese tourism-related companies going forward, giving a clearer picture of how the sector is doing as the Chinese economy slows and consumers become more cautious.
Previously released national data showed the sector was holding up quite well during the long Lunar New Year holiday in February despite the economic slowdown. The number of domestic trips during the weeklong period rose 34.3% to 474 million, while domestic tourism spending was up by an even stronger 47.3% to 632.7 billion yuan ($87 billion), according to government data.
But Fosun Tourism&rsquo;s data wasn&rsquo;t nearly so buoyant. Business volume at the company&rsquo;s Atlantis Sanya mega-resort was up just 4.5% to 576 million yuan during the first quarter, according to the company&rsquo;s quarterly update. The number of visits to the resort rose at a slightly faster rate of 7.5% to 2.1 million. But in a slightly ominous sign, the average daily room rate was actually down 2.8% to 2,500 yuan.
Here we should point out that year-ago figures for the resort might have been artificially high, since China ended its Covid restrictions at the end of 2022 and &ldquo;revenge travel&rdquo; was at a peak in January and February 2023 as many people took some of their first major vacations in three years during those months.
<h3>Dead&nbsp;Cat Bounce</h3>
Fosun tourism shares got a lift from the update, rising more than 5% in early trade on Tuesday. But the jump was a bit of a &ldquo;dead cat bounce,&rdquo; since the stock was previously at an all-time low, and it&rsquo;s quite likely the shares could resume their downward trend later this week.
Even after the slight rally, the stock is still well behind its peers in terms of valuation. It trades at a forward price-to-earnings (P/E) ratio of just 10, compared to a 20 for&nbsp;Trip.com&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcom#NASDAQ">TCOM</a>), China&rsquo;s leading online travel agent that has a similar mix of domestic and international business. While Fosun Tourism&rsquo;s shares are down sharply this year, Trip.com&rsquo;s stock has risen about 40% over that period.
While Sanya Atlantis posted single-digit gains, the performance was slightly better at Club Med, whose worldwide chain of resorts accounts for more than 80% of Fosun Tourism&rsquo;s business. The chain&rsquo;s business volume rose 15.2% to 6.08 billion yuan in the first quarter, while average occupancy at its rooms rose 1.4 percentage points to 76.9%. Its average bed rate rose 8.8% to 2,190 yuan.
Here, we should point out that Fosun Tourism is doing quite a bit better now, at least in terms of business volume, than it was before the pandemic. The company&rsquo;s latest overall first-quarter business volume of 7.16 billion yuan was up nearly 50% from the 4.8 billion yuan it reported in the first quarter of 2019. The big jump most likely reflects the fact that Fosun Tourism, like many of its peers, continued to upgrade existing properties and build new ones during the pandemic, in anticipation of business eventually returning to normal.
While the first-quarter numbers don&rsquo;t look too impressive, Fosun Tourism also didn&rsquo;t impress investors too much with its results for all of 2023 released last month. Those results show its revenue rose 25% last year to 17.2 billion yuan. Within the total, Sanya Atlantis posted much stronger revenue growth, with the figure nearly doubling to 1.76 billion yuan from 897 million yuan a year earlier. Club Med revenue rose by a slower 22% to 14.6 billion yuan, reflecting the fact that its business is mostly outside China and thus already began to rebound in 2022.
Still, the company&rsquo;s overall revenue growth last year was well behind the 122% growth for Trip.com, whose revenue reached 44.5 billion yuan for the period.
The bottom line is that investors have recently become quite bearish on Fosun Tourism, partly due to its underwhelming post-Covid rebound. But the bigger reason is probably the cloud hanging over the company due to its parent&rsquo;s financial difficulties, meaning no one is really sure what Fosun Tourism might look like a year from now &ndash; assuming it continues exists in its current form.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Asia

Travel

FOSUF

FSNGF

TCOM

Fosun Tourism's Post-Covid Holiday Fizzles

Benchmark analyst Subash Chandra maintains Matador Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>) with a Buy and lowers the price target from $71 to $62.

MTDR

Benchmark Maintains Buy on Matador Resources, Lowers Price Target to $62

Helius Medical Technologies Inc (HSDT) is down -5.17%% today. HSDT has an Overall Score of 35. Find out what this means to you and get the rest of the rankings on HSDT!See Full HSDT ReportHSDT stock closed at $5.80 and is down -$0.30 during pre-market trading. Pre-market tends to be more volatile due to significantly lower

Premarket Mover: Helius Medical Technologies Inc (HSDT) Down 5.17%

Helius Medical Technologies Inc (HSDT) stock has fallen -54.96% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives HSDT stock a score of  31 out of a possible 100. That rank is chiefly influenced by a long-term technical score of

Is Helius Medical Technologies Inc (HSDT) Stock Worth a Buy Friday?

Helius Medical Technologies GAAP EPS of -$1.47 beats by $2.30, revenue of $0.13M misses by $0.12M

Helius Medical Technologies, Inc. (HSDT) Q4 2023 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Helius Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/hsdt-stock-quote/">HSDT</a>) just reported results for the fourth quarter of 2023.<ul><li>Helius Medical Tech reported earnings per share of -$1.47. This was above the analyst estimate for EPS of -$3.77.</li><li>The company reported revenue of $134,000.</li><li>This was 46.40% worse than the analyst estimate for revenue of $250,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/hsdt-stock-earnings-helius-medical-tech-for-q4-of-2023/">HSDT Stock Earnings: Helius Medical Tech Beats EPS, Misses Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

HSDT Stock Earnings: Helius Medical Tech Beats EPS, Misses Revenue for Q4 2023

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Helius Medical Technologies (HSDT – Research Report). ...

Helius Medical Technologies (HSDT) Gets a Buy from Maxim Group

Helius Medical Technologies signs partnership with Lovell Government Services

FibroGen, Acorda Therapeutics, Enveric Biosciences among healthcare movers

EC, ABAT and BORR among pre-market losers

Helius Medical files to sell Class A common stock, warrants

ABAT

ABIO

ACHL

ACOR

ADXN

BORR

ENVB

FGEN

FLGC

GCTS

HSDTW

JZXN

KTRA

KYCH

LGVC

ONMD

PTPI

REPX

VNDA

XTIA

Press Releases

Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists' Ability to Customize PoNS Therapy® to Improve Gait in People with MS

Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients

Opinion

Thinking about buying stock in Helius Medical Technologies, Peraso, GDS Holdings, Everbridge, or Petros Pharmaceuticals?

Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller

Thinking about buying stock in SoundHound AI, Macy's, Ainos, Helius Medical Technologies, or Renalytix?

Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference

Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke

Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™